AI assistant
Acticor Biotech — Report Publication Announcement 2021
Dec 16, 2021
1070_iss_2021-12-16_5d18228f-fbd4-438c-85c0-8b0df0e2f661.pdf
Report Publication Announcement
Open in viewerOpens in your device viewer
Acticor Biotech announces its 2022 financial agenda
Paris, France, December 16, 2021 at 06:00 pm CET– ACTICOR BIOTECH (ISIN: FR0014005OJ5 – ALACT), a clinical stage biopharmaceutical company, an INSERM spin-off, is developing an innovative treatment for acute thrombotic diseases, including ischemic strokes, today announces it 2022 financial agenda.
| Events | Dates* |
|---|---|
| 2021 Full-Year Results | March 30th 2022 |
| 2022 Half-Year Results | September 22th 2022 |
| *Information subject to change. |
About ACTICOR BIOTECH
Acticor Biotech, a clinical stage biopharmaceutical company, a spin-off from INSERM (the French National Institute of Health and Medical Research), is developing an innovative treatment for acute thrombotic diseases, including ischemic strokes. Acticor Biotech is developing glenzocimab (ACT017), a humanized monoclonal antibody fragment (Fab). This drug candidate is directed against a new target of major interest, platelet glycoprotein VI (GPVI), and inhibits its action. This target is involved in thrombus growth but not in physiological hemostasis, and thus limits the bleeding risk associated with its inhibition.
Acticor Biotech is listed on Euronext Growth Paris since November 2021 (ISIN: FR0014005OJ5 - ALACT).
For further information, please go to www.acticor-biotech.com
Contacts
ACTICOR BIOTECH Gilles AVENARD CEO [email protected]
Sophie BINAY, PhD Deputy CEO and Scientific Director [email protected] NewCap Mathilde BOHIN / Olivier BRICAUD Investor Relations [email protected] Tel.: +33 (0)1 44 71 94 95
NewCap
Annie-Florence LOYER Media Relations [email protected] Tel.: +33 (0)1 44 71 00 12